Abstract
The poor imaging characteristics of 131I have resulted in the use of alternative radionuclides for radiolabelling monoclonal antibodies. Clinical imaging studies have shown that, in addition to the more suitable energy of emission of 111In over 131I for gamma camera detection, the 111In-labelled antibody appears to clear from the blood-stream at a faster rate than that of 131I-labelled antibody, resulting in greater tumour-to-background image contrast.
However, measurements of the activity in blood samples from patients demonstrate that both 131I- and 111In-labelled anitbodies clear from the circulation at similar rates. This discrepancy is probably due to the different biological fates of the two radionuclides and warrants further scientific study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armitage NC, Perkins AC, Pimm MW, Farrands PA, Baldwin RW, Hardcastle JD (1984) The localisation of an anti-tumour monoclonal antibody (791T/36) in gastrointestinal tumours. Br J Surg 71:407–412
Armitage NC, Perkins AC, Pimm MV, Wastie ML, Baldwin RW, Hardcastle JD (1985) Imaging of primary and metastatic colorectal cancer using an 111In-labelled antitumour monoclonal antibody 7917/36. Nucl Med Commun 6:623–631
Begent RHJ, Green A, Bagshawe KD, Jones BE, Keep PA, Searle F, Jewkes RF, Barrat GM, Ryman BE (1982) Liposomally entrapped second antibody improves tumour imaging with radio-labelled (first) anti-tumour antibody. Lancet II:739–742
Berche C, Mach J-P, Lumbroso JD, Langlais C, Aubry F, Buchegger F, Carrel S, Rougier P, Parmentier C, Tubiana M (1982) Tomoscintigraphy for detecting gastroentestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen. Br Med J 285:1447–1451
DeLand FH, Kim EE, Simmons G, Goldenberg DM (1980) Imaging approach in radioimmunodetection. Cancer Res 40:3046–9
Epenetos AA, Britton KE, Mather S, Shepherd J, Granowska M, Taylor-Papadimitriou J, Nimmon CC, Durbin H, Hawkins LE, Malpas JS, Bodmer WF (1982) Targeting of iodine-123 labelled tumour-associated monoclonal antibodies to ovarian, breast and gastrointestinal tumours. Lancet II:999–1005
Fairweather DS, Bradwell AR, Dykes PW, Vaughan AT, Watson-James SF, Chandler S (1983) Improved tumour localisation using indium-111 labelled antibodies. Br Med J 287:167–170
Farrands PA, Perkins AC, Pimm MV, Hardy JG, Embleton MJ, Baldwin RW, Hardcastle JD (1982) Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody. Lancet II:397–400
Farrands PA, Perkins AC, Sully I, Hopkins JS, Pimm MV, Baldwin RW, Hardcastle JD (1983) Localisation of human osteosarcoma by anti-tumour monoclonal antibody. J Bone Joint Surg [Br] 65:638–640
Larson SM, Brown JP, Wright PW, Carrasquillo JA, Hellstrom I, Hellstrom KE (1983) Imaging of melanoma with I-131-labelled monoclonal antibodies. J Nucl Med 24:123–129
Mach JP, Buchegger F, Forni M, Ritschard J, Berche C, Lumbroso JD, Mchrege M, Giradet C, Accolla RS, Carrel S (1981) Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today 2:239–249
Perkins AC, Whalley DR, Hardy JG (1984) Physical approach for the reduction of dual radionuclide image subtraction artefacts in immunoscintigraphy. Nucl Med Commun 5:501–512
Perkins AC, Pimm MV, Birch MK (1985) Preparation and characterisation of 111In-labelled 791T/36 monoclonal antibody for tumour immunoscintigraphy. Eur J Nucl Med 10:296–301
Pimm MV, Embleton MJ, Perkins AC, Price MR, Robins RA, Robinson GR, Baldwin RW (1982) In vivo localisation of antiosteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts. Int J Cancer 30:75–85
Pimm MV, Perkins AC, Rowe RE, Armitage NC, Baldwin RW (1985A) Characterisation of blood-borne radiolabel and detection of anti-mouse IgG. Antibodies in cancer patients receiving radiolabelled monoclonal antibody for diagnostic immunoscintigraphy. Proceedings of the Second European Symposium on Radiopharmacy and Radiopharmaceuticals. Nighoff/Junk, The Hague (in press)
Pimm MV, Perkins AC, Baldwin RW (1985B) Differences in tumour and normal tissue concentrations of iodine and indium labelled monoclonal antibody. II. Biodistribution studies in mice with human tumour xenografts. Eur J Nucl Med 8:300–304
Rainsbury RM, Ott RJ, Westwood JH, Kalirai TS, Coombes RC, McCready VR, Neville AM, Gazel JC (1983) Localisation of metastatic breast carcinoma by a monoclonal antibody chelate labelled with Indium III. Lancet II:934–938
Symonds EM, Perkins AC, Pimm MV, Baldwin RW, Hardy JG, Williams DA (1985) Clinical implications for immunoscintigraphy in patients with ovarian malignancy: a preliminary study using monoclonal antibody 791T/36. Br J Obstet Gynaecol 92:270–276
Williams MR, Perkins AC, Campbell FC, Pimm MV, Hardy JG, Wastie ML, Blamey RW, Baldwin RW (1984) The use of monoclonal antibody 791T/36 in the immunoscintigraphy of primary and metastatic carcinoma of the breast. Clin Oncol 10:375–381
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Perkins, A.C., Pimm, M.V. Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. Eur J Nucl Med 11, 295–299 (1985). https://doi.org/10.1007/BF00252340
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00252340